Zentalis Pharmaceuticals, Inc.
ZNTL
$1.43
-$0.08-5.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.37% | 7.36% | 17.46% | 7.72% | 17.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.37% | 5.07% | 13.90% | 8.51% | 11.73% |
| Operating Income | 26.18% | 11.99% | 3.79% | 8.79% | -11.73% |
| Income Before Tax | 43.43% | 37.64% | 32.10% | 9.09% | -23.29% |
| Income Tax Expenses | 129.45% | 129.90% | 130.02% | -43.65% | -28.14% |
| Earnings from Continuing Operations | 43.26% | 37.37% | 31.75% | 9.18% | -23.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -75.44% | -52.38% | -67.71% | -47.89% | -62.87% |
| Net Income | 43.24% | 37.37% | 31.73% | 9.15% | -23.39% |
| EBIT | 26.18% | 11.99% | 3.79% | 8.79% | -11.73% |
| EBITDA | 26.28% | 12.02% | 3.77% | 8.81% | -11.82% |
| EPS Basic | 48.92% | 45.69% | 43.02% | 22.09% | -0.39% |
| Normalized Basic EPS | 39.57% | 43.07% | 40.13% | 38.78% | 15.76% |
| EPS Diluted | 48.91% | 45.69% | 43.02% | 22.11% | -0.47% |
| Normalized Diluted EPS | 39.55% | 43.06% | 40.12% | 38.77% | 15.76% |
| Average Basic Shares Outstanding | 8.72% | 14.09% | 20.58% | 21.21% | 23.76% |
| Average Diluted Shares Outstanding | 8.83% | 14.21% | 20.71% | 21.34% | 23.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |